Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Ostuzzi

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|February 28, 2026
Antipsychotic medicines for schizophrenia: time to move forwardCorrado Barbui, Giovanni Ostuzzi
The Lancet. Psychiatry|November 21, 2021
Expanding access to long-acting antipsychotics in low-income and middle-income countriesGiovanni Ostuzzi, Corrado Barbui
The Lancet. Psychiatry|January 12, 2024
Combining randomised and observational evidence in schizophrenia: how real is the real world?Giovanni Ostuzzi, Corrado Barbui
Lancet (London, England)|February 27, 2022
Preventing relapse in schizophrenia needs better evidenceGiovanni Ostuzzi, Corrado Barbui
Evidence-Based Mental Health|June 19, 2014
Beneficial and harmful consequences of prepartum and postpartum antidepressant exposureCorrado Barbui, Giovanni Ostuzzi
The Lancet. Psychiatry|August 31, 2017
Regulatory meta-analyses for the evaluation of psychotropic medicinesCorrado Barbui, Marianna Purgato, Giovanni Ostuzzi
Evidence-Based Mental Health|October 27, 2009
SSRI plus supportive care more effective than supportive care alone for mild to moderate depressionCorrado Barbui, Giovanni Ostuzzi, Andrea Cipriani
The Lancet. Child & Adolescent Health|September 30, 2023
The WHO Model List of Essential Medicines for Children needs its own identity: the case of psychotropic medicinesDavide Papola, Giovanni Ostuzzi, Chiara Gastaldon, et al.
Cancer Treatment Reviews|June 30, 2015
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysisGiovanni Ostuzzi, Laura Benda, Enrico Costa, et al.
Epidemiology and Psychiatric Sciences|May 11, 2022
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countriesGiovanni Ostuzzi, Chiara Gastaldon, Davide Papola, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|February 28, 2026
Antipsychotic medicines for schizophrenia: time to move forwardCorrado Barbui, Giovanni Ostuzzi
The Lancet. Psychiatry|November 21, 2021
Expanding access to long-acting antipsychotics in low-income and middle-income countriesGiovanni Ostuzzi, Corrado Barbui
The Lancet. Psychiatry|January 12, 2024
Combining randomised and observational evidence in schizophrenia: how real is the real world?Giovanni Ostuzzi, Corrado Barbui
Lancet (London, England)|February 27, 2022
Preventing relapse in schizophrenia needs better evidenceGiovanni Ostuzzi, Corrado Barbui
Evidence-Based Mental Health|June 19, 2014
Beneficial and harmful consequences of prepartum and postpartum antidepressant exposureCorrado Barbui, Giovanni Ostuzzi
The Lancet. Psychiatry|August 31, 2017
Regulatory meta-analyses for the evaluation of psychotropic medicinesCorrado Barbui, Marianna Purgato, Giovanni Ostuzzi
Evidence-Based Mental Health|October 27, 2009
SSRI plus supportive care more effective than supportive care alone for mild to moderate depressionCorrado Barbui, Giovanni Ostuzzi, Andrea Cipriani
The Lancet. Child & Adolescent Health|September 30, 2023
The WHO Model List of Essential Medicines for Children needs its own identity: the case of psychotropic medicinesDavide Papola, Giovanni Ostuzzi, Chiara Gastaldon, et al.
Cancer Treatment Reviews|June 30, 2015
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysisGiovanni Ostuzzi, Laura Benda, Enrico Costa, et al.
Epidemiology and Psychiatric Sciences|May 11, 2022
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countriesGiovanni Ostuzzi, Chiara Gastaldon, Davide Papola, et al.
Pageof 9